Redx Pharma Clinical Trial for Pioneering Crohn's Disease Medication
Redx Pharma has initiated a Phase I clinical trial for RXC008, a new class of ROCK inhibitor aimed at treating fibrostenotic Crohn's disease. This study, focusing on safety and pharmacokinetics, marks a significant step in addressing a condition currently limited to surgical interventions. Results are anticipated by year's end.
The following article originally appeared in Proactive Investors.
Redx Pharma PLC said it has kicked off a phase I clinical trial for RXC008, a 'first-in-class' ROCK inhibitor treatment targeting fibrostenotic Crohn's disease.
This study aims to assess the safety and pharmacokinetic profile of the drug - in other words, its activity in the body over some time, including the processes by which RXC008 is absorbed, distributed in the body, localised in the tissues, and excreted.
It will be assessed in healthy volunteers with the results from the study expected by the end of this year.
Chief executive Lisa Anson told investors: "We are delighted to confirm that the first participant has been dosed in the RXC008 phase I clinical study.
"RXC008 is a potential first-in-class treatment for patients with fibrostenotic Crohn's disease, a debilitating condition where successive surgeries are the only treatment option available today.
"This milestone represents the sixth asset from Redx to enter clinical development, continuing our strong track record in small molecule drug discovery as a result of our world-class medicinal chemistry and translational science expertise."
Fibrostenotic Crohn's disease is a specific complication of Crohn's disease characterised by the formation of strictures in the intestine, leading to a narrowing of the bowel that can significantly affect the function of the gastrointestinal tract.
These strictures are typically fibrotic, meaning they involve thickening and scarring of the bowel wall.
The main difference between general Crohn's disease and fibrostenotic Crohn's is the nature of these complications.
For more, please find the original story source here.
